MedPath
Found 4 clinical trials|View Analysis
Sort by:

Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)

Phase 1
Active, not recruiting
Conditions
Advanced Solid Tumor
Interventions
Biological: Nemvaleukin alfa
Biological: Pembrolizumab
First Posted Date
2020-10-19
Last Posted Date
2024-06-07
Lead Sponsor
Mural Oncology, Inc
Target Recruit Count
78
Registration Number
NCT04592653
Locations
πŸ‡ΊπŸ‡Έ

START Mountain, West Valley City, Utah, United States

πŸ‡ΊπŸ‡Έ

MD Anderson Cancer Center, Houston, Texas, United States

πŸ‡ΊπŸ‡Έ

START Midwest, Grand Rapids, Michigan, United States

and more 3 locations

A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer

Phase 2
Completed
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
First Posted Date
2019-10-30
Last Posted Date
2024-10-16
Lead Sponsor
Mural Oncology, Inc
Target Recruit Count
14
Registration Number
NCT04144517
Locations
πŸ‡ΊπŸ‡Έ

Mural Oncology Investigational Site, Austin, Texas, United States

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
Biological: ALKS 4230
Biological: Pembrolizumab
First Posted Date
2019-03-04
Last Posted Date
2024-03-05
Lead Sponsor
Mural Oncology, Inc
Target Recruit Count
116
Registration Number
NCT03861793
Locations
πŸ‡°πŸ‡·

Inha University Hospital, Incheon, Korea, Republic of

πŸ‡°πŸ‡·

Seoul National University Bundang Hospital, Seongnam, Korea, Republic of

πŸ‡°πŸ‡·

Seoul National University Hospital, Seoul, Korea, Republic of

and more 7 locations

A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2016-06-14
Last Posted Date
2024-01-24
Lead Sponsor
Mural Oncology, Inc
Target Recruit Count
243
Registration Number
NCT02799095
Locations
πŸ‡¦πŸ‡Ί

Mural Oncology Investgational Site, Albury, New South Wales, Australia

πŸ‡ͺπŸ‡Έ

Mural Oncology Investigational Site, Valencia, Spain

πŸ‡¨πŸ‡¦

Alkermes Investigational Site, Toronto, Ontario, Canada

Β© Copyright 2025. All Rights Reserved by MedPath